title: Decreased expression of FOXF2 as new predictor of poor prognosis in stage I non-small cell lung cancer.
abstract: BACKGROUND
  Forkhead box F2 (FOXF2) is relatively limited to the adult lung, but its contribution to non-small cell lung cancer (NSCLC) prognosis is unclear.
  
  
  RESULTS
  FOXF2 mRNA levels in NSCLC were lower than that in paired normal lung tissues (P = 0.012). The FOXF2low patients had shorter survival time than the FOXF2high patients (P = 0.024) especially in stage I (P = 0.002), chemotherapy (P = 0.018) and < 60 age groups (P = 0.002). Lower FOXF2 mRNA levels could independently predict poorer survival for patients with NSCLC (HR = 2.384, 95% CI = 1.241-4.577; P = 0.009), especially in stage I (HR =4.367, 95% CI =1.599-11.925; P = 0.004). The two independent datasets confirmed our findings.
  
  
  METHODS
  We examined FOXF2 mRNA levels in 84 primary NSCLC and 8 normal lung tissues using qRT-PCR. Rank-sum tests and chi-square tests were used to assess the differences among groups with various clinicopathological factors. Kaplan-Meier tests were used to compare survival status in patients with different FOXF2 mRNA levels. Cox proportional hazards regression model was used to evaluate the predictive value of FOXF2 mRNA level in NSCLC patients. Independent validation was performed using an independent dataset (98 samples) and an online survival analysis software Kaplan-Meier plotter (1928 samples).
  
  
  CONCLUSIONS
  Our results demonstrated that decreased FOXF2 expression is an independent predictive factor for poor prognosis of patients with NSCLC, especially in stage I NSCLC.
authors.affiliation: Translational Medicine Research Center, Shanxi Medical University, Taiyuan 030001, China.|Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: Peng-Zhou
authors.initials: PZ
authors.lastname: Kong
authors.affiliation: School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
authors.forename: Guang-Ming
authors.initials: GM
authors.lastname: Li
authors.affiliation: Department of General Surgery, The Second Hospital of JingZhou, JingZhou 434000, China.|Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
authors.forename: Yin
authors.initials: Y
authors.lastname: Tian
authors.affiliation: Translational Medicine Research Center, Shanxi Medical University, Taiyuan 030001, China.|Department of Oncology, The First Hospital, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Song
authors.affiliation: Translational Medicine Research Center, Shanxi Medical University, Taiyuan 030001, China.|Department of Cell Biology and Genetics, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: RuYi
authors.initials: R
authors.lastname: Shi
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry / Q000401:mortality* / Q000473:pathology; D005260:Female; D051858:Forkhead Transcription Factors / Q000032:analysis* / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000737:chemistry / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000032:analysis
chemical_list: C486413:FOXF2 protein, human; D051858:Forkhead Transcription Factors; D012333:RNA, Messenger
keywords: FOXF2; clinical stage; non-small-cell lung carcinoma; survival